Supplementary Information File

Synthesis of New Hybrid Derivatives from Metronidazole and Eugenol Analogues as Trypanocidal Agents

Mônica Fraccarolli Pelozo^a, Giovanna Fiori Serpa Lima^a, Luana Sueli Silva^b, Ivo Santana Caldas^b, Diogo Teixeira Carvalho^a, Stefânia Neiva Lavorato^c, Jamie Anthony Hawkes^a, Cleydson Finotti Cordeiro^a, Lucas Lopardi Franco^{a*}.

^a Faculdade de Ciências Farmacêuticas. Universidade Federal de Alfenas, MG, 37130-001, Brazil,

^b Instituto de Ciências Biomédicas. Universidade Federal de Alfenas, MG, 37130-001, Brazil

^c Centro de Ciências Biológicas e Saúde, Universidade Federal do Oeste da Bahia, BA, 47810-047 Brazil

*Corresponding author: Lucas Lopardi Franco (lucas.franco@unifal-mg.edu.br). Faculdade de Ciências Farmacêuticas, Universidade Federal de Alfenas, Rua Gabriel Monteiro da Silva, 700, Alfenas, MG, 37130-001, Brazil.

Fourier Transform InfraRed Spectroscopy (FTIR) was performed on a Shimadzu[®] Affinity-1 spectrometer using a zinc selenide attenuated total reflectance (ATR) sampling accessory supplied by Pike Technologies[®] (USA). Readings were taken at room temperature, 32 scans per analysis, resolution of 4.0cm⁻¹, range from 4000-600cm⁻¹.

Nuclear Magnetic Resonance Spectroscopy (NMR) was performed on a Bruker[®] 300 spectrometer. All ¹H experiments (including the 2D HSQC & HMQC experiments) were recorded at 300 MHz and ¹³C experiments were recorded at 75 MHz. Samples were dissolved into CDCl₃ as a solvent apart from compounds [1], [2] and [6] which, due to their low solubility in CDCl₃ required the use of DMSO-*d*₆. Chemical shifts were recorded in parts per million (ppm) based on the corresponding solvent. The following abbreviations are used for spin multiplicity: s = singlet, d = doublet, t = triplet.

Liquid Chromatography–Mass Spectrometry (LC-MS) analysis was performed on a Waters Acquity UPLC H-Class system; comprising a quaternary solvent manager attached to a triple-quadrupole (Acquity TQD) mass spectrometer. The samples were prepared in acetonitrile, and the mobile phase was acetonitrile spiked with 0.1% formic acid. The flow rate and injection volume were 0.4 mL / min and 10.0 μ L, respectively. Electrospray ionisation (ESI) with positive ionisation mode was found to be suitable and optimised as follows: cone voltage between 3 and 40V, capillary at 3KV and extractor 3V, source block temperature 120 °C, desolvation line 500 °C, nitrogen was used as the nebulising gas at 1000 litres/hour. The output signals were monitored and processed using Empower 3 software.

Contents

- 1. Structures and Chemical Data for Compounds [1]-[9]
- 2. Compound [1] = [2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl methanesulfonate]
- 2.1. FTIR (ATR) Spectrum of Compound 1
- 2.2. ¹H NMR Spectrum [300 MHz, DMSO-d₆ (ppm)] of Compound [1]
- 2.3. ${}^{13}C NMR Spectrum [75 MHz, DMSO-d_6 (ppm)] of Compound [1]$
- 3. Compound [2] = [1-(2-azidoethyl)-2-methyl-5-nitro-1H-imidazole]
- 3.1. FTIR (ATR) Spectrum of Compound 2
- 3.2. ¹H NMR Spectrum [300 MHz, DMSO-d₆ (ppm)] of Compound [2]
- 3.3. ¹³C NMR Spectrum [75 MHz, DMSO-d₆ (ppm)] of Compound [2]
- 4. Compound [3] = [4-allyl-2-methoxy-1-(prop-2-yn-1-yloxy)benzene]
- 4.1. FTIR (ATR) Spectrum of Compound [3]
- 4.2. ¹H NMR Spectrum [300 MHz, CDCl₃ (ppm)] of Compound [3]
- 4.3. ¹³C NMR Spectrum [75 MHz, CDCl₃ (ppm)] of Compound [3]
- 5. Compound [4] = [2-methoxy-1-(prop-2-yn-1-yloxy)-4-propylbenzene]
- 5.1. FTIR (ATR) Spectrum of Compound [4]
- 5.2. ¹H NMR Spectrum [300 MHz, CDCl₃ (ppm)] of Compound [4]

- 5.3. ¹³C NMR Spectrum [75 MHz, CDCl₃ (ppm)] of Compound [4]
- 6. Compound [5] = [1-methoxy-2-(prop-2-yn-1-yloxy)benzene]
- 6.1. FTIR (ATR) Spectrum of Compound [5]
- 6.2. ¹H NMR Spectrum [300 MHz, CDCl₃ (ppm)] of Compound [5]
- 6.3. ¹³C NMR Spectrum [75 MHz, CDCl₃ (ppm)] of Compound [5]
- 7. Compound [6] = [(1-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl)-1H-1,2,3-triazol-4-yl)methanol]
- 7.1. FTIR (ATR) Spectrum of Compound [6]
- 7.2. LCMS (ESI) Spectrum of Compound [6]
- 7.3. ¹H NMR Spectrum [300 MHz, DMSO- d_6 (ppm)] of Compound [6]
- 7.4. ¹³C NMR Spectrum [75 MHz, DMSO-d₆ (ppm)] of Compound [6]
- 8. Compound [7] = [4-((2-methoxyphenoxy)methyl)-1-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl)-1H-1,2,3-triazole]
- 8.1. FTIR (ATR) Spectrum of Compound [7]
- 8.2. LCMS (ESI) Spectrum of Compound [7]
- 8.3. ¹H NMR Spectrum [300 MHz, CDCl₃ (ppm)] of Compound [7]
- 8.4. ¹H NMR 2D HSQC Spectrum [300 MHz, CDCl₃ (ppm)] (complete) Spectrum of Compound [7]
- 8.5. ¹H NMR 2D HSQC Spectrum [300 MHz, CDCl₃ (ppm)] (expanded) Spectrum of Compound [7]
- 8.6. ¹H NMR 2D HMQC Spectrum [300 MHz, CDCl₃ (ppm)] (complete) Spectrum of Compound [7]
- 8.7. ¹H NMR 2D HMQC Spectrum [300 MHz, CDCl₃ (ppm)] (expanded) Spectrum of Compound [7]
- 8.8. ¹³C NMR Spectrum [75 MHz, CDCl₃ (ppm)] of Compound [7]
- $9. Compound \ [8] = [4-((4-allyl-2-methoxyphenoxy)methyl)-1-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl)-1H-1,2,3-triazole]$
- 9.1. FTIR (ATR) Spectrum of Compound [8]
- 9.2. LCMS (ESI) Spectrum of Compound [8]
- 9.3. ¹H NMR Spectrum [300 MHz, CDCl₃ (ppm)] of Compound [8]
- 9.4. ¹³C NMR Spectrum [75 MHz, CDCl₃ (ppm)] of Compound [8]
- 10. Compound [9] = [4-((2-methoxy-4-propylphenoxy)methyl)-1-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl)-1H-1,2,3-triazole] = [4-((2-methoxy-4-propylphenoxy)methyl)-1-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl)-1H-1,2,3-triazole] = [4-((2-methoxy-4-propylphenoxy)methyl)-1-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl)-1H-1,2,3-triazole] = [4-((2-methoxy-4-propylphenoxy)methyl)-1-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl)-1H-1,2,3-triazole] = [4-((2-methyl-5-nitro-1H-imidazol-1-yl)ethyl)-1H-1,2,3-triazole] = [4-((2-methyl-5-nitro-1H-imidazol-1-yl)ethyl] = [4-((2-methyl-1H-imidazol-1+yl)ethyl] = [4-
- 10.1. FTIR (ATR) Spectrum of Compound [9]
- 10.2. LCMS (ESI) Spectrum of com Compound [9]
- 10.3. ¹H NMR Spectrum [300 MHz, CDCl₃ (ppm)] of Compound [9]
- 10.4. ¹³C NMR Spectrum [75 MHz, CDCl₃ (ppm)] of Compound [9]

1. Structures and Chemical Data for Compounds [1]-[9]



| $\begin{bmatrix} 6 \end{bmatrix} \xrightarrow{\mathbf{N}}_{\mathbf{O}_2 \mathbf{N}} \xrightarrow{\mathbf{O}_2 \mathbf{N}}_{\mathbf{N}} \mathbf{CH}_3$ | $[7] \qquad N \qquad O_2 N \qquad N \qquad CH_3$ | $[8] \qquad N \qquad O \qquad O$ | $[9] \qquad N \qquad O_2 N \qquad N \qquad O_2 N \qquad N \qquad CH_3$ |
|---|---|---|---|
| Chemical Formula : C ₉ H ₁₂ N ₆ O ₃ | Chemical Formula : C ₁₆ H ₁₈ N ₆ O ₄ | Chemical Formula : C ₁₉ H ₂₂ N ₆ O ₄ | Chemical Formula : C ₁₉ H ₂₄ N ₆ O ₄ |
| Exact Mass: 252.10 | Exact Mass: 358.14 | Exact Mass: 398.17 | Exact Mass: 400.19 |
| Molecular Weight: 252.23 | Molecular Weight: 358.36 | Molecular Weight: 398.42 | Molecular Weight: 400.44 |
| Predicted m/z : 252.10 (100.0%), | Predicted m/z : 358.14 (100.0%), | Predicted m/z : 398.17 (100.0%), | Predicted m/z : 400.19 (100.0%), |
| 253.10 (9.7%), 253.09 (2.2%) | 359.14 (17.3%), 359.14 (2.2%), | 399.17 (20.5%), 399.17 (2.2%), | 401.19 (20.5%), 401.18 (2.2%), |
| Calculated Elemental Analysis: | 360.15 (1.4%) | 400.18 (2.0%) | 402.19 (2.0%) |
| C:42.86, H:4.80, N:33.32, | Calculated Elemental Analysis: | Calculated Elemental Analysis: | Calculated Elemental Analysis: |
| O:19.03 | C:53.63, H:5.06, N:23.45, | C:57.28, H:5.57, N:21.09, | C:56.99, H:6.04, N:20.99, |
| | O:17.86 | O:16.06 | O:15.98 |

Note: the data presented in this table was calculated using the Analysis tool within the ChemBioDraw[®] Program, by CambridgeSoft Corp.

2. Compound [1] = [2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl methanesulfonate]

2.1. FTIR (ATR) Spectrum of Compound [1]

Assigned bands (cm⁻¹): 3058 (C4-H), 2805 (C6,7,8-H), 1351 (S=O), 1118 (S=O), 1285 (N=O), 1108 (N=O), 1055 (C-O).



2.2. ¹H NMR Spectrum [300 MHz, DMSO-d₆ (ppm)] of Compound [1]

Assigned signals (ppm): 8.07 [s, 1H, H4], 4.65 [t, ${}^{3}J = 6.3$ Hz, 2H, H8], 4.55 [t, ${}^{3}J = 6.3$ Hz, 2H, H7], 3.15 [s, 3H, -SO₂C<u>H</u>₃], 2.46 [s, 3H, H6].



2.3. ¹³C NMR Spectrum [75 MHz, DMSO-d₆ (ppm)] of Compound [1]

Assigned signals (ppm): 152.18 [C1], 138.89 [C5], 133.51 [C4], 68.95 [C8], 45.54 [C7], 37.14 [-SO₂CH₃], 13.46 [C6].



3. Compound [2] = [1-(2-azidoethyl)-2-methyl-5-nitro-1H-imidazole]

3.1. FTIR (ATR) Spectrum of Compound [2]

Assigned bands (cm⁻¹): 3055 (C4-H), 2811 (C6,7,8-H), 2108 (N=N=N), 1285 (N=O), 1108 (N=O), 1051 (C-O).



3.2. ¹H NMR Spectrum [300 MHz, DMSO-d₆ (ppm)] of Compound [2]

Assigned signals (ppm): 8.02 [s, 1H, H4], 4.44 [t, ${}^{3}J = 6.4$ Hz, 2H, H8], 3.73 [t, ${}^{3}J = 6.4$ Hz 2H, H7], 2.44 [s, 3H, H6].



3.3. ¹³C NMR Spectrum [75 MHz, DMSO-d₆ (ppm)] of Compound [2]

Assigned signals (ppm): 151.99 [C2], 138.79 [C5], 133.60 [C4], 50.47 [C8], 45.39 [C7], 14.43 [C6].



4. Compound [3] = [4-allyl-2-methoxy-1-(prop-2-yn-1-yloxy)benzene]

4.1. FTIR (ATR) Spectrum of Compound [3]

Assigned bands (cm⁻¹): 3311 (C10-H), 3010 (CAr-H), 2105 (C=C), 1504 (C=C), 1035 (C-O).



4.2. ¹*H* NMR Spectrum [300 MHz, CDCl₃ (ppm)] of Compound [3]

Assigned signals (ppm): 6.95 [m, 4H, H3'-6'], 4.77 [s, 2H, H8'], 3.87 [s, 3H, H7'], 2.51 [s, 1H, H10].



4.3. ¹³C NMR Spectrum [75 MHz, CDCl₃ (ppm)] of Compound [3]

Assigned signals (ppm): 149.7 [C1'], 146.7 [C2'], 122.3 [C4'], 120.7 [C5'], 114.4 [C6'], 111.8 [C3'], 78.5 [C9], 75.7 [C10], 56.6 [C8'], 55.8 [C7'].



5. Compound [4] = [2-methoxy-1-(prop-2-yn-1-yloxy)-4-propylbenzene]

5.1. FTIR (ATR) Spectrum of Compound [4]

Assigned bands (cm⁻¹): 3308 (C10-H), 3005 (CAr-H), 2111 (C=C), 1511 (C=C), 1045 (C-O).



5.2. ¹H NMR Spectrum [300 MHz, CDCl₃ (ppm)] of Compound [4]

Assigned signals (ppm): 6.93 [d, ${}^{3}J = 8,1$ Hz, 1H, H6'], 6.72 [m, 2H, H3', H5'], 4.72 [s, 2H, H8'], 4.11 [s, 1H, H10], 3.65 [s, 3H, H7'], 2.51 [t, ${}^{3}J = 7.6$ Hz, 2H, Ar-C<u>H</u>₂], 1.61 [s, ${}^{3}J = 7.6$ Hz, 2H, -C<u>H</u>₂], 0.93 [t, ${}^{3}J = 7.6$ Hz, 3H, -C<u>H</u>₃].



5.3. ¹³C NMR Spectrum [75 MHz, CDCl₃ (ppm)] of Compound [4]

Assigned signals (ppm): 149.9 [C2'], 149.4 [C1'], 136.9 [C4'], 120.1 [C5'], 114.5 [C6'], 112.2 [C3'], 78.9 [C9], 75.5 [C10], 56.9 [C8'], 55.8 [C7'], 37.7 [Ar-<u>CH</u>₂], 29.7 [<u>C</u>H₂'], 14,2 [<u>C</u>H₃].



Compound [5] = [1-methoxy-2-(prop-2-yn-1-yloxy)benzene]

5.4. FTIR (ATR) Spectrum of Compound [5]

Assigned bands (cm⁻¹): 3299 (C10-H), 3007 (CAr-H), 2115 (C=C), 1499 (C=C), 1045 (C-O).



5.5. ¹*H* NMR Spectrum [300 MHz, CDCl₃ (ppm)] of Compound [5]

Assigned signals (ppm): 6.97 [d, ${}^{3}J = 8.6$ Hz, 1H, H6'], 6.74 [m, 2H, H3', H5'], 5.96 [m, 1H, C<u>H</u>=CH₂], 5.08 [m, 2H, CH=C<u>H</u>₂], 4.74 [d, ${}^{3}J = 2.4$ Hz, 2H, H8'], 3.86 [s, 3H, H7'], 3.34 [d, ${}^{3}J = 6.8$ Hz, 2H, Ar-C<u>H</u>₂'], 2.49 [t, ${}^{3}J = 2.4$ Hz, 2H, H10].



5.6. ¹³C NMR Spectrum [75 MHz, CDCl₃ (ppm)] of Compound [5]

Assigned signals (ppm): 149.6 [C2'], 145.1 [C1'], 137.5 [<u>C</u>H=CH₂], 133.2 [C4'], 120.3 [C5'], 115.8 [CH=<u>C</u>H₂],114.5 [C6'], 112.3 [C3'], 78.8 [C9], 75.7 [C10], 56.9 [C8'], 55.8 [C7'], 39.9 [Ar-<u>C</u>H₂].



6. Compound [6] = [(1-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl)-1H-1,2,3-triazol-4-yl)methanol]

6.1. FTIR (ATR) Spectrum of Compound [6]

Assigned bands (cm⁻¹): 3059 (C10-H), 3015 (CAr-H), 1504 (C=C), 1284 (N=O), 1118 (N=O), 1051 (C-O).



6.2. LCMS (ESI) Spectrum of Compound [6]





6.3. ¹H NMR Spectrum [300 MHz, DMSO-d₆ (ppm)] of Compound [6]

Assigned signals (ppm): 8.04 [s, 1H, H4], 7.87 [s, 1H, H10'], 5.25 [t, ³*J* = 5.7 Hz, 1H, OH], 4.79 [t, ³*J* = 5.7 Hz, 2H, H8], 4.68 [t, ³*J* = 5.7 Hz, 2H, H7], 4.47 [d, ³*J* = 5.7 Hz, 2H, H11], 1.83 [s, 3H, H6].



6.4. ¹³C NMR Spectrum [75 MHz, DMSO-d₆ (ppm)] of Compound **{6**]

Assigned signals (ppm): 151.8 [C2], 149.9 [C9'], 138.9 [C5], 133.7 [C4], 124.1 [C10'], 53.3 [C8], 49.0 [C8'], 46.7 [C7], 13.3 [C6]



7. Compound [7] = [4-((2-methoxyphenoxy)methyl)-1-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl)-1H-1,2,3-triazole] 7.1. FTIR (ATR) Spectrum of Compound [7]

Assigned bands (cm⁻¹): 3055 (C10-H), 3011 (CAr-H), 1507 (C=C), 1294 (N=O), 1201 (N=O), 1032 (C-O).



7.2. LCMS (ESI) Spectrum of Compound [7]



LC-MS (ESI) m/z calculated for $C_{16}H_{18}N_6O_4 = 358.14$, m/z + H⁺ = 359.14. Found 359.08.

7.3. ¹*H* NMR Spectrum [300 MHz, CDCl₃ (ppm)] of Compound [7]

Assigned signals (ppm): 7.97 [s, 1H, H4], 7.40 [s, 1H, H10'], 6.91 [m, 4H, H3'-H6'], 5.25 [s, 2H, H8'], 4.77 [s, 4H, H7, H8], 3.85 [s, 3H, H7'], 1.92 [s, 3H, H6].







7.5. ¹H NMR 2D HSQC Spectrum [300 MHz, CDCl₃ (ppm)] (expanded) of Compound [7]

7.6. ¹H NMR 2D HMQC Spectrum [300 MHz, CDCl₃ (ppm)] (complete) of Compound [7]

7.7. ¹H NMR 2D HMQC Spectrum [300 MHz, CDCl₃ (ppm)] (expanded) of Compound [7]

7.8. ¹³C NMR Spectrum [75 MHz, CDCl₃ (ppm)] of Compound [7]

Assigned signals (ppm): 151.3 [C2], 149.6 [C9'], 147.2 [C1'], 145.3 [C2'], 138.1 [C5], 133.8 [C4], 123.8 [C10'], 122.1 [C5'], 120.1 [C6'], 114.1 [C4'], 111.9 [C3'], 62.7 [C8'], 55.9 [C7'], 49.6 [C8], 46.4 [C7], 13.3 [C6].

8. Compound [8] = [4-((4-allyl-2-methoxyphenoxy)methyl)-1-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl)-1H-1,2,3-triazole] 8.1. FTIR (ATR) Spectrum of Compound [8]

Assigned signals (cm⁻¹): 3033 (C10-H), 3014 (CAr-H), 1518 (C=C), 1255 (N=O), 1237 (N=O), 1035 (C-O).

8.2. LCMS (ESI) Spectrum of Compound [8]

LC-MS (ESI) m/z calculated for $C_{19}H_{22}N_6O_4 = 398.17$, m/z + H⁺ = 399.17. Found 399.13.

8.3. ¹*H NMR Spectrum* [300 *MHz*, *CDCl*₃ (*ppm*)] of Compound [8]

Assigned signals (ppm): 7.97 [s, 1H, H4], 7.40 [s, 1H, H10'], 6.87 [d, ${}^{3}J = 7.8$ Hz, 1H, H6'], 6.72 [m, H3', H5'], 5.92 [m, 1H, C<u>H</u>=CH₂], 5.22 [s, 2H, H8'], 5.07 [m, 2H, C=C<u>H₂]</u>, 4.76 [m, 4H, H7, H8], 3.85 [s, 3H, H7'], 3.31 [d, ${}^{3}J = 8.0$ Hz, 2H, Ar-C<u>H₂]</u>, 1.94, [s, 3H, H6].

8.4. ¹³C NMR Spectrum [75 MHz, CDCl₃ (ppm)] of Compound [8]

Assigned signals (ppm): 151.3 [C2], 149.5 [C9'], 145.5 [C2'], 145.41 [C1'], 137.5 [C5], 134.4 [C4'], 133.8 [C4], 133.5 [C <u>C</u>H=CH₂], 123.8 [C10'], 120.5 [C5'], 115.8 [CH=<u>C</u>H₂]], 114.5 [C6'], 112.4 [C3'], 62.9 [C8'], 55.8 [C7'], 49.6 [C8], 46.4 [C7], 39.8 [Ar-<u>C</u>H₂], 13.4 [C6].

9. Compound [9] = [4-((2-methoxy-4-propylphenoxy)methyl)-1-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl)-1H-1,2,3-triazole] 9.1. FTIR (ATR) Spectrum of Compound [9]

Assigned bands (cm⁻¹): 3049 (C10-H), 3010 (CAr-H), 1508 (C=C), 1285 (N=O), 1215 (N=O), 1033 (C-O).

9.2. LCMS (ESI) Spectrum of Compound [9]

LC-MS (ESI) m/z calculated for $C_{19}H_{24}N_6O_4 = 400.19$, m/z + H⁺ = 401.19. Found 401.16.

9.3. ¹H NMR Spectrum [300 MHz, CDCl₃ (ppm)] of Compound [9]

Assigned signals (ppm): 7.97 [s, 1H, H4], 7.39 [s, 1H, H10'], 6.84 [d, ${}^{3}J = 8.1$ Hz, 1H, H6'], 6.67 [m, H3', H5'], 5.21 [s, 2H, H8'], 4.75 [s, 4H, H7, H8], 3.81 [s, 3H, H7'], 2.50 [t, ${}^{3}J = 7.9$ Hz, 2H, Ar-C<u>H</u>₂], 1.95, [s, 3H, H6], 1.60 [s, ${}^{3}J = 7.3$ Hz, 2H, -C<u>H</u>₂], 0.94 [t, ${}^{3}J = 7.3$ Hz, 3H, -C<u>H</u>₃].

9.4. ¹³C NMR Spectrum [75 MHz, CDCl₃ (ppm)] of Compound [9]

Assigned signals (ppm): 149.3 [C2], 145.5 [C9'], 145.2 [C2'], 136.8 [C1'], 133.9 [C5], 133.6 [C4'], 133.5 [C4], 123.8 [C10'], 120.3 [C5'], 114.3 [C6'], 112.3 [C3'], 62.9 [C8'], 55.8 [C7'], 49.6 [C8], 46.4 [C7], 37.7 [Ar-<u>C</u>H₂], 24.7 [<u>C</u>H₂], 13.8 [<u>C</u>H₃], 13.4 [C6].

